Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.

ABSTRACT: Background:Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use disorder. Objective:To evaluate the cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone. Design:Cost-effectiveness analysis alongside a previously reported randomized clinical trial of 570 adults in 8 U.S. inpatient or residential treatment programs. Data Sources:Study instruments. Target Population:Adults with opioid use disorder. Time Horizon:24-week intervention with an additional 12 weeks of observation. Perspective:Health care sector and societal. Interventions:Buprenorphine-naloxone and extended-release naltrexone. Outcome Measures:Incremental costs combined with incremental quality-adjusted life-years (QALYs) and incremental tim

SUBMITTER: Murphy SM 

PROVIDER: S-EPMC6581635 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature